ProCE Banner Activity

CE / CME

Advances in Predictive Biomarkers for Immune Checkpoint Inhibitors in Lung Cancer: Why, Who, and How

Multimedia
Watch this CME/MOC-certified on-demand Webcast of a CCO symposium at ASCP 2019 to gain insights from both medical oncology and pathology experts on the optimal use of predictive biomarkers for immune checkpoint inhibitors in the care of patients with lung cancer.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

US Physicians : maximum of 1.00 Medical Knowledge MOC point(s)

Released: October 08, 2019

Expiration: October 07, 2020

No longer available for credit.

Share

Faculty

Heather J. Jackson

Heather J. Jackson, PhD, FNP-BC, NEA-BC, FAANP

Associate Professor
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University School of Nursing
Administrative Director of Advanced Practice
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

Sanjay Mukhopadhyay

Sanjay Mukhopadhyay, MD

Director, Pulmonary Pathology
Department of Pathology
Cleveland Clinic
Cleveland, Ohio

Sandip P. Patel

Sandip P. Patel, MD

Associate Professor
Department of Medicine
Division of Hematology/Oncology
University of California San Diego
San Diego, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Bristol Myers Squibb

Genentech TEXT Only

Merck Sharp & Dohme Corp.

Target Audience

This program is intended for pathologists and other healthcare providers who treat and manage patients with lung cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate the clinical utility of predictive biomarkers for immune checkpoint inhibitor response in lung cancer by line of therapy, available therapeutic alternatives, and health economic considerations
  • Compare and contrast the different methodologies and assays for identifying biomarkers of response to immune checkpoint inhibitors in different lung cancer histologies and treatment settings
  • Implement best practices for biomarker testing/interpretation of results to guide treatment selection in different lung cancer histologies and treatment settings
  • Summarize ongoing research regarding the utility of biomarkers, PD-L1, MSI/MMR, tumor mutational burden, DNA damage repair, T-cell functional state, composite biomarkers, or other host factors predictive of response to and/or toxicities associated with immune checkpoint inhibitors

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director Disclosure

Program Director

Heather J. Jackson, PhD, FNP-BC, NEA-BC, FAANP

Associate Professor
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University School of Nursing
Administrative Director of Advanced Practice
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

H. Jack West, MD, has disclosed that he has received consulting fees from Ariad/Takeda, Bristol-Myers Squibb, Celgene, Genentech/Roche, and Merck and fees for non-CME/CE services from Ariad/Takeda, Genentech/Roche, Lilly, and Merck.

Faculty Disclosure

Primary Author

Sanjay Mukhopadhyay, MD

Director, Pulmonary Pathology
Department of Pathology
Cleveland Clinic
Cleveland, Ohio

Sanjay Mukhopadhyay, MD, has no relevant conflicts of interest to report.

Sandip P. Patel, MD

Associate Professor
Department of Medicine
Division of Hematology/Oncology
University of California San Diego
San Diego, California

Sandip P. Patel, MD, has disclosed that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Illumina, Lilly, and Tempus.

Staff Disclosure

Staff

Jason J. Everly, PharmD

Jason Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has disclosed that his spouse/partner has ownership interest in and receives a salary from AstraZeneca.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Pathology Continuing Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Lifelong Learning (Part II) and Self-Assessment Module (SAM) points in the American Board of Pathology’s Maintenance of Certification (MOC) Program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.

Learners must complete the post-test with a passing score of 70%. Physicians may follow the post test link provided at the end of the activity evaluation to claim ABPath MOC credit.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 08, 2019, through October 07, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ knowledge of and competence in assessing biomarkers to guide the use of immune checkpoint inhibitors in the treatment of patients with lung cancer.